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Augmentation of antitumour activity of defucosylated chimeric
anti-CCR4 monoclonal antibody in SCID mouse model of adult
T-cell leukaemia/lymphoma using G-CSF
Adult T-cell leukaemia/lymphoma (ATLL) has a very poor
prognosis (Uchiyama et al, 1977; Taylor & Matsuoka, 2005).
Because tumour cells from most ATLL patients express CCR4
(Ishida et al, 2003), we postulated that this molecule might
represent a novel molecular target for immunotherapy and
developed a chimeric anti-CCR4 monoclonal antibody (mAb),
KM2760 (Niwa et al, 2004). Antibody-dependent cellular
cytotoxicity (ADCC) is one of the most important mechanisms
of action of therapeutic mAb (Ishida & Ueda, 2006). Although
ADCC depends on the cytotoxic activity of effector cells, such
as natural killer (NK) cells, monocytes/macrophages and
neutrophils, these cells are commonly qualitatively suppressed
and quantitatively reduced in cancer patients. To overcome
this problem, the Fc region of KM2760 is defucosylated, which
results in enhanced ADCC (Niwa et al, 2004). We have
previously reported that a robust KM2760-induced ADCC
mediated by autologous effector cells were triggered in some
ATLL patients (Ishida et al, 2004), whereas little autologous
KM2760-induced ADCC was observed in other ATLL patients,
especially those with few effector cells in their peripheral blood
mononuclear cells (data not shown). These ﬁndings prompted
us to seek ways in which to augment KM2760-induced ADCC
using the immunomodulatory agent granulocyte colony-stim-
ulating factor (G-CSF; Nartograstim, Kyowa Hakko Kogyo
Incorporation, Tokyo, Japan), which is commonly used
clinically.
Human G-CSF increased granulocyte counts in a dose-
dependent manner in severe-combined immunodeﬁcient
(SCID) mice (Fig 1A). Subsequently, we evaluated KM2760-
induced antitumour activity in the ATLL tumour-bearing
mouse model with or without G-CSF in the disseminated
setting. The ATLL cell line S-YU (Imada et al, 1996) was
positive for CCR4 by ﬂow cytometric analysis (data not
shown). 1Æ5 · 10
7 S-YU cells were inoculated s.c. into SCID
mice. The tumour-bearing mice were divided into four groups
of ﬁve each for treatment with KM2760 or control (saline),
KM2760 plus G-CSF or G-CSF alone, to ensure that the mean
tumour volumes were same in each group. KM2760 (20 mg/
kg) or saline injections into the tail veins of the mice were
started 12 d after tumour inoculation, and continued weekly
for 4 weeks. The signiﬁcance of differences in the tumour
volume among the groups was estimated by the Mann–
Whitney U-test. In this study, P <0 Æ05 was considered
signiﬁcant. G-CSF (10 lg/mouse) was injected s.c. into SCID
mice on days 0–6 and 14–20 from the start of KM2760
treatment. Mean tumour volumes in KM2760 recipients and
control mice 27 d after the start of KM2760 treatment were
1174 ± 409 and 5015 ± 1033 mm
3 respectively (P =0 Æ0090).
KM2760 combined with G-CSF treatment yielded an even
more robust antitumour effect, with all recipients achieving
complete remission, i.e. subcutaneous S-YU tumours com-
pletely vanished. The difference between the tumour volume in
animals treated with KM2760 plus G-CSF and those with
KM2760 alone was highly signiﬁcant (P =0 Æ0053) (Fig 1B and
C). None of the mice in the present study showed evidence of
toxicity that could be attributed to the KM2760 and/or the
G-CSF injections. These ﬁndings indicate that human G-CSF
signiﬁcantly augments the antitumour activity of KM2760 in
the ATLL tumour-bearing mouse model.
Next, we explored the mechanisms whereby human G-CSF
augments the anti-ATLL activity of KM2760 in vivo. Because
KM2760 mediates only ADCC and not complement-dependent
cytotoxicity or direct anti-proliferative activity (Ishida et al,
2004), it was hypothesized that G-CSF augmented KM2760-
induced ADCC in vivo. Standard 4-h
51Cr-release assays were
performed using pooled granulocytes from 14 G-CSF-injected
or 15 naı ¨ve SCID mice as effector cells (E) and S-YU cells as
targets (T) at E/T ratios of 50:1, 100:1 and 200:1. However,
KM2760 (10 lg/ml) failed to induce any ADCC against S-YU
cells in the presence of granulocytes from either G-CSF-injected
or naı ¨ve SCID mice at any E/T ratio (data not shown). We next
investigated the phagocytic activity of G-CSF-primed mono-
cytes/macrophages, because we recently reported the impor-
tance of the innate monocyte/macrophage network, not the NK
cell network, to deplete target cells through FcR-dependent
pathways during antibody-based immunotherapy in mice
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phages were prepared from peritoneal exudate cells of 14 SCID
mice receiving 10 lg G-CSF twice (at 20 h and 5 h before
testing) or 15 naı ¨ve SCID mice. As S-YU does not express
CD20, rituximab (Chugai Pharmaceutical Co., Ltd, Tokyo,
Japan) was used as a control mAb for KM2760. PKH26 (Sigma-
Aldrich, St Louis, MO, USA) labelled S-YU (1 · 10
4) and
pooled monocytes/macrophages from 14 G-CSF-injected or 15
naı ¨ve SCID mice (5 · 10
4) were co-cultured with or without
KM2760 or rituximab at a ﬁnal concentration of 10 lg/ml for
1 h. The cells were stained with phycoerythrin cyanin 5
(PECy5)-conjugated anti-F4/80 mAb (Serotec Ltd, Oxford,
UK), which speciﬁcally binds mouse monocytes/macrophages,
and analysed by BD FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA, USA) as previously described (Ishida
et al, 2006). The percentage of spontaneous, rituximab-
induced, and KM2760-induced phagocytosis of S-YU mediated
by pooled monocytes/macrophages from 15 naı ¨ve SCID mice
was 8Æ6%, 13Æ4% and 21Æ5% respectively, whereas these values
from 14 G-CSF primed SCID mice were 19Æ2%, 17Æ8% and
30Æ6% respectively (Fig 2A and B). The formula used to
calculate the percentage of phagocytosis of S-YU is shown in
Fig 2C. These ﬁndings indicate that human G-CSF augments
not only natural phagocytosis but also KM2760-induced
phagocytosis of S-YU by mouse monocytes/macrophages,
although the underlying mechanisms require further clariﬁca-
tion. The data presented here are the ﬁrst to address the
potential G-CSF-induced augmentation of monocytes/macro-
phages in the antitumour activity of a therapeutic mAb in an
in vivo animal model.
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Fig 1. KM2760-induced potent antitumour activity in the Adult T-cell leukaemia/lymphoma (ATLL) tumour-bearing mouse model in the thera-
peutic setting (A) Total white blood cell, granulocyte and monocyte counts in blood of mice injected with 1, 3 or 10 lg granulocyte colony-
stimulating factor (G-CSF) on days 1–7 were measured. Each group consists of three mice, and the blood cell counts are presented as mean + SD
(x10
9 cells/l). Arrows, G-CSF injection; d, total white blood cells; h, granulocytes; and D, monocytes. (B) Antitumour activity of KM2760 against
pre-established subcutaneous S-YU tumours. Tumour volume was calculated by the following formula: Tumour volume (mm
3)=0 Æ5 · (major
diameter) · (minor diameter)
2. Injections of KM2760 or saline were started when tumours were about 609 mm
3 (12 d after S-YU inoculation). The
tumour volume is presented as mean (mm
3). Arrowheads indicate KM2760 or control injections and arrows indicate G-CSF or control injections.
Each group consists of ﬁve mice. d, control (saline); s, KM2760; , G-CSF; and h, KM2760 plus G-CSF. A signiﬁcant differences between the
groups are indicated by #P <0 Æ01 or *P <0 Æ05. (C) The photographs of each mouse were taken at day 27 from the start of treatment.
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antitumour activity induced by next-generation defucosylated
therapeutic mAb (Carter, 2006; Ishida et al, 2006) was strongly
augmented by the immunomodulatory agent G-CSF in vivo.
This ﬁnding has encouraged us to conduct of a phase-I clinical
trial of the completely defucosylated anti-CCR4 mAb in
patients with CCR4-positive T-cell lymphomas including
ATLL (ClinicalTrials.gov Identiﬁer: NCT00355472) to develop
a novel treatment strategy for patients with ATLL. In the near
future, the efﬁcacy of combination treatments including anti-
CCR4 mAb and immunomodulatory agents against refractory
ATLL will be assessed in clinical trials.
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Fig 2. Granulocyte colony-stimulating factor (G-CSF)-enhanced KM2760-induced phagocytosis mediated by mouse monocytes/macrophages
(A) Mouse monocytes/macrophages phagocytosis of S-YU cells in the presence or absence of KM2760. Rituximab was the control chimeric mAb.
Pooled monocytes/macrophages from peritoneal exudate cells of 14 naı ¨ve or 15 G-CSF-injected severe combined immunodeﬁcient (SCID) mice were
used for phagocytosis assays. The E/T ratio was ﬁxed at 5, and the incubation period was 1 h. Flow cytometric analyses of PKH26-labelled S-YU cells
stained with phycoerythrin cyanin 5 (PECy5)-conjugated anti-F4/80 mAb are shown. (B) The percentage of phagocytosis for each group is indicated
as a bar graph. (C) The formula to calculate the percentage phagocytosis of S-YU is illustrated. S-YU cells phagocytosed by monocytes/macrophages
are indicated in the upper right quadrant as R2.
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Molecular determination of the breakpoints of a 161 556 bp
deletion at chromosome 13q34 that presented as severe factor
VII deﬁciency in a neonate
We have previously described a newborn infant girl with severe
factor VII (FVII) deﬁciency that was caused by the com-
pounding effects of two novel mutations (Hewitt et al, 2005).
The proband inherited a new missense mutation (F7
g.3907G>A) from her father together with a previously
undetected deletion from her mother. Real time polymerase
chain reaction (PCR) analysis of the proband’s genomic DNA
revealed that both F7 and F10 were deleted on this allele.
Because of the maternal deletion, DNA sequence analysis of the
proband’s genomic DNA was restricted to the paternal allele
resulting in apparent pseudo-homozygosity in this region. In
the past, it has been difﬁcult to map allelic deletions at the
nucleotide level because of the lack of ﬂanking DNA sequence
information. However, using sequence data from the Human
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